Use of trans-(tetrachlorobis(1H-indazole)ruthenate (III)) for the treatment of cancer

• 收藏
• 分享

专利权人:

Intezyne Technologies

发明人:

Bakewell, Suzanne,Sethuraman, Jyothi

申请号：

AU2017227705

公开号：

AU2017227705A1

申请日:

2017.03.01

申请国别(地区):

AU

年份:

2018

代理人:

摘要：

IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/